Oxford Immunotec gets $26 million in Series D

Oxford Immunotec has closed a second Series D round that raised $26 million. The financing was led by New Leaf Venture Partners.

Oxford, which manufactures and markets T cell-based diagnostics, will use the funds to advance its pipeline and continue the commercialization of its T-SPOT T cell measurement technology.

Vijay Lathi, a managing director at NLV Partners, joined Oxford's board of directors in connection with the financing. Others in the round included newcomer Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.

- see Oxford's release for more

ALSO: AppDynamics closed its $11 million Series B round. The round, led by Lightspeed Venture Partners and Greylock Partners, will fund the company's expansion in the application performance management market. Release

Suggested Articles

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.

Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise.